Insmed reported $-81.83M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Cytokinetics USD -167.09M 12.08M Sep/2026
DBV Technologies USD -64.8M 16.9M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -81.83M 19.48M Sep/2026
Novartis USD 1.84B 2.39B Sep/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026